Shifamed
VC Fund
Campbell, United States
Shifamed is a progressive medical technology incubator that combines human-centered design, specialized engineering expertise, and in-house R&D facilities to develop new medical products from initial concept to successful commercial release.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Shifamed invests in
Stages Shifamed invests in
Countries Shifamed invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Claudio Argento
|
|||
Mariam Maghribi
|
|||
Amr Salahieh
|
|||
David Voris
|
|||
Greg Payne
|
Investment Focus
Industry
- Health Care 5 (63%)
- Medical 4 (50%)
- Medical Device 4 (50%)
- Wellness 1 (13%)
Stage
- Series B 5 (63%)
- Series A 1 (13%)
- Series C 1 (13%)
- Series D 1 (13%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Claudio Argento
CTO
|
CTO | Total investments: 0 | Find email | |
|
Mariam Maghribi
Chief Business Officer
|
Chief Business Officer | Total investments: 0 | Find email | |
|
Amr Salahieh
Founding President and Chief Executive Officer
|
Founding President and Chief Executive Officer | Total investments: 0 | Find email | |
|
David Voris
Chief Financial Officer
|
Chief Financial Officer | Total investments: 0 | Find email | |
|
Greg Payne
Head of Sales and Marketing
|
Head of Sales and Marketing | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Supira Medical
|
Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions. Its technology is designed to provide temporary mechanical circulatory support, aiming to improve patient outcomes during high-risk procedures or acute heart failure management. The company focuses on advancingminimally invasive solutions to enhance cardiovascular care. | $40M / Series D / Nov 21, 2023 | |
Akura Medical
|
Akura Medical offers products and services centered on mechanical thrombectomy and imaging software for venous thromboembolism treatment. Its Katana Thrombectomy System uses a steerable catheter with integrated jet-based technology to access clot material, break it down, and support clot removal during a procedure. The system provides proceduralfeedback intended to help clinicians assess clot engagement and clearance while operating the device. Akura Medical also develops NavIQ, a software tool that transforms CT angiograms into 3D vascular models that display clot location and morphology to guide procedural planning. Together, these products form a workflow that supports physicians from pre-procedure assessment through clot extraction in cases involving pulmonary embolism and related VTE conditions. | $35M / Series B / Oct 03, 2023 | |
Myra Vision
|
Myra Vision designs a treatment that allows maximum IOP reduction for patients with moderate to severe glaucoma. It is a privately held portfolio company of Shifamed LLC. The company accelerates its development of the first-of-its-kind treatment for patients with moderate to severe glaucoma through its latest funding. | $25M / Series B / Jun 26, 2023 | |
Tioga Cardiovascular
|
Tioga Medical, a privately held portfolio company of Shifamed LLC, is focused on providing elegant valve replacement solutions for mitral and tricuspid applications that are procedurally simpler and use a less invasive, transcatheter approach. | $30M / Series C / Feb 09, 2023 | |
Adona Medical
|
Adona Medical is a privately held portfolio company of Shifamed that innovates interventional approaches for heart failure, a complex and progressive condition impacting approximately 6.5 million patients in the US and as many as 26 million patients globally. Adona's platform will overcome the shortcomings of existing treatment options andenable providers to improve care for heart failure patients. | $37.5M / Series B / Apr 29, 2022 | |
|
Akura Medical
|
Akura Medical offers products and services centered on mechanical thrombectomy and imaging software for venous thromboembolism treatment. Its Katana Thrombectomy System uses a steerable catheter with integrated jet-based technology to access clot material, break it down, and support clot removal during a procedure. The system provides proceduralfeedback intended to help clinicians assess clot engagement and clearance while operating the device. Akura Medical also develops NavIQ, a software tool that transforms CT angiograms into 3D vascular models that display clot location and morphology to guide procedural planning. Together, these products form a workflow that supports physicians from pre-procedure assessment through clot extraction in cases involving pulmonary embolism and related VTE conditions. | $25M / Series A / Jan 10, 2022 | |
|
Tioga Cardiovascular
|
Tioga Medical, a privately held portfolio company of Shifamed LLC, is focused on providing elegant valve replacement solutions for mitral and tricuspid applications that are procedurally simpler and use a less invasive, transcatheter approach. | $30M / Series B / Jul 07, 2021 | |
|
Supira Medical
|
Supira Medical is a clinical-stage company that develops catheter-based circulatory support devices for patients with heart conditions. Its technology is designed to provide temporary mechanical circulatory support, aiming to improve patient outcomes during high-risk procedures or acute heart failure management. The company focuses on advancingminimally invasive solutions to enhance cardiovascular care. | $35M / Series B / Mar 05, 2020 |
Co-Investors
Cormorant Asset Management
8 deals together
The Capital Partnership
8 deals together
AMED Ventures
6 deals together
415 Capital
2 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Shifamed invest in?
Shifamed invests primarily in Health Care, Medical and Medical Device startups, most often at Series B and Series A stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Shifamed?
Public channels for Shifamed include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Shifamed?
The team at Shifamed includes Claudio Argento (CTO), Mariam Maghribi (Chief Business Officer) and Amr Salahieh (Founding President and Chief Executive Officer). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
